

Multimodality Imaging and Heart Disease

Milind Y. Desai, MD FACC
Tomsich Department of Cardiovascular
Medicine,
Heart and Vascular Institute,
Cleveland Clinic
Disclosures: None

Objectives


- Introduction
- Different imaging modalities and their strengths/weaknesses
- Incorporation of multi-modality imaging in different clinical indications
- Appropriateness criteria
- Conclusions

Introduction

- CVD: biggest source of morbidity and mortality
- Many new imaging technologies
- Advances in imaging outpacing our ability to digest the changes
- Cost, risks, what to do with the information?
 - In 2009, CCF did more than 61000 echoes, 7500 CTs and 2500 CMR's

Imaging and Real Data: A Major Disconnect

- ACC/AHA guidelines:
 - 750 recommendations related to cardiac imaging



Some sobering information !!!!!

Recent data shows that only 38 % coronary angiographies were clinically indicated

Patel: NEJM 2010

Different Noninvasive imaging modalities

- **Echocardiography**
 - Mainstay of noninvasive CV diagnosis
- **Myocardial perfusion scintigraphy**
 - SPECT, PET
- **Cardiac magnetic resonance**
- **Cardiac computed tomography**

Utility and Limitations


Imaging technique	Potential diagnostic utility	Limitations
Echo	<ul style="list-style-type: none"> * LV thickness * valves and hemodynamics * global and regional LV function * Ischemia * Viability 	<ul style="list-style-type: none"> * Limited acoustic windows * Inaccurate wall thickness measurements * Suboptimal assessment of subvalvular apparatus
MPI	<ul style="list-style-type: none"> * Ischemia * Viability * coronary flow reserve (PET) 	<ul style="list-style-type: none"> * Limited availability (PET) * Expensive (PET) * High radiation exposure
CMR	<ul style="list-style-type: none"> * LV dimensions * Cardiac morphology * Tissue characterization * Regional myocardial mechanics * Aortic pathology 	<ul style="list-style-type: none"> * Limited availability * Multiple device-related contraindications
MDCT	<ul style="list-style-type: none"> * CAD, * LV function and morphology * Emerging role in viability * Aortic pathology 	<ul style="list-style-type: none"> * Radiation exposure * Nephrotoxicity * Emerging data

Radiation Doses for Medical Procedures

Diagnostic procedure	Typical effective dose (mSv)	Equivalent period of natural background radiation
Natural background radiation	3-4 (range 1.5-7.5)	1 year
Chest X-ray (PA and lateral)	0.04	6 days
Transatlantic flight	0.03	5 days
Lung perfusion study (99m Tc)	1	4-6 months
Calcium scoring	0.8-2	3-6 months
CT head	2	8 months
Cardiac catheterization (diagnostic)	3-4	1 year
64-slice MDCT (with dose modulation)	Male: 4.8-10 Female: 6.8-14	2-3 years
CT angio prospective	2-4	1 year
Rb-82 PET myocardial perfusion	16	4-5 years
Tl-201 stress and reinjection	25.1	6-8 years
Dual isotope (Tl-201 and Tc-99m)	27.3*	7-9 years

*Thompson RE, Cutler SJ. J Nucl Cardiol 2006;12:19-23.

Lifetime Attributable Cancer Risk



Noninvasive Diagnostic Testing in Ischemic Heart Disease


Anybody wonder why CAD is such an epidemic ?




Different Stress Testing Modalities

- **Exercise**
 - Treadmill (either with echo or nuclear)
 - Sitting bicycle
 - Supine bicycle
- **Pharmacological**
 - Dobutamine-- Contractility and HR increase (either with echo, nuclear or CMR)
 - Dipyridamole – vasodilating (mostly nuclear)
 - Adenosine – vasodilating (mostly nuclear, CMR, ?? CT is emerging)


Exercise echocardiography




Stress MPI



Sensitivity Comparison of Different Testing Modalities



Specificity of Different Stress Testing Modalities




Comparison between SPECT (²⁰¹Tl and ^{99m}Tc) and PET-⁸²Rb

	SPECT	PET
« excellent » images	62%	78%
Interpretation certainty (normal,abnormal)	81%	96%
Diagnostic accuracy	71%	87%

Bateman T.M. et al J Nucl Cardiol 2006; 13: 24-33


Adenosine MRI



Adenosine stress MRI: Sensitivity 100%
Specificity 93%


Arai JACC 2006

Dobutamine Echo vs. CMR




Nagel et al. Circ 1999;99:763-70

Stress Echo and Prognosis





Category	No at risk	1	2	3	4	5
F<1.25	1929	1808	1348	890	518	299
M<1.25	1945	1783	1376	920	568	321
F≥1.25	538	457	327	210	120	63
M≥1.25	1372	1104	846	551	345	199

Arruda-Olsen et al JACC 2002



But life is not that simple


**Quest to search for the
“predisposed” patient**



Coronary Calcium Scoring

Possibly indicated in asymptomatic individuals with intermediate Framingham risk score

Coronary Calcium & Framingham Risk Score



Greenland P, et al. JAMA. 2004 14;291(2):210-5

MDCT Coronary Angiography

- Diagnostic utility in patients with intermediate likelihood of CAD
- High number of unnecessary invasive procedures†:
 - 40% of women
 - 20-25% of men
 - ? potential in patients to exclude CAD

†Kugelmass AD. J Am Coll Cardiol 2001;37:497A*

Meta-Analysis of MDCT for Coronary Artery Stenosis ≥ 16 Slice


•27 studies with ≥ 16 slice CT between 2002-2006

Analysis	N	Sensitivity (95% CI)	Specificity (95% CI)	LR + (95% CI)	LR - (95% CI)	DOR (95% CI)
Per segment	22,798	0.81 (0.72-0.89)	0.93 (0.90-0.97)	21.54 (13.07-35.48)	0.11 (0.06-0.21)	189.32 (93.47-383.43)
Per vessel	2726	0.82 (0.80-0.85)	0.91 (0.90-0.92)	11.80 (6.75-20.64)	0.08 (0.02-0.32)	146.45 (31.95-671.21)
Per patient	1570	0.96 (0.94-0.98)	0.74 (0.65-0.84)	5.36 (3.45-8.33)	0.05 (0.03-0.09)	133.05 (57.29-308.98)


STRENGTH IS HIGH SENSITIVITY AND NEGATIVE PREDICTIVE VALUE

Hamon M. J Am Coll Cardiol 2006; 48:1896-1910


Case: 48-year old female presenting to ER with recurrent chest pressure. EKG and enzymes negative. Smoker, hypertensive. Underwent 256-slice coronary CT angiography



Advanced CAD



Correlation of Coronary CT and Perfusion




Stenoses in CT not closely correlated to an abnormal MPI

Schuijff et al, JACC 2006

Outcomes after MDCT >50% stenosis

CCTA Result	Risk Adjusted Hazard Ratio (95% CI)	P value
Any severe stenosis	2.14(0.95-4.81)	0.07
Moderate or severe coronary stenosis (per seg)	1.05(1.02-1.09)	<0.01
Any severe proximal stenosis	1.44(0.74-2.81)	NS
Any left main stenosis	2.65(1.37-5.12)	<0.01
Segment involvement score (per seg involved)	1.16(1.05-1.28)	0.004
Three vessel coronary plaque, any severity	2.04(0.99-4.20)	0.05





Cumulative Survival in Patients with Moderate (>50%) Plaque by CCTA



- N = 1127 - patients with symptoms
 - 70% with intermediate or high pretest probability

- Endpoint: Death - by Social Security Death Index

Min et al. J Am Coll Cardiol 2007;50:1161-70



Diagnostic Accuracy of CT for CABG Evaluation: A meta-analysis

Analysis Type and No. of Studies (n=15)	No. of Grafts	Sensitivity (%)	Specificity (%)	Positive Predictive Value (%)	Negative Predictive Value (%)
Graft obstruction, 15	2023	97.6 (96.0,98.6)	96.7 (95.6,97.5)	92.7 (90.5,94.6)	98.9 (98.2,99.4)
16-section, 9	1047	96.9 (94.2,98.6)	96.4 (94.8,97.6)	91.3 (87.6,94.2)	98.8 (97.7,99.4)
64-section, 6	976	98.1 (96.0,99.2)	96.9 (95.2,98.4)	94.1 (91.0,96.3)	99.1 (98.0,99.7)
Occlusion, 10	1308	99.3 (97.3,99.9)	98.7 (97.9,99.3)	95.4 (92.2,97.5)	99.8 (99.3,100)
Stenosis, 9	871	94.4 (87.5,98.2)	98.0 (96.7,98.8)	84.2 (75.6,90.7)	99.4 (98.5,99.8)

Hamon M. Radiology 2008; 247 (3): 679-86

Role in Pre-op Planning before Redo OHS

- In patients undergoing redo OHS CT helps to assess
 - Location of prior grafts
 - Distance of grafts from sternum
 - Patency of grafts
 - Proximity of right sided cardiac structures
 - Proximity of aorta
 - Degree of ascending aortic calcification
- Necessary to adopt preventive surgical strategies



Kamdar A, Desai M. ATS April 2008

Inappropriate Indications for CT

Indication	Appropriateness Criteria (Median Score)
Detection of CAD: Symptomatic-Evaluation of Chest Pain Syndrome (use of CT angiogram)	I (2)
<ul style="list-style-type: none"> High pre-test probability of CAD 	I (2)
Detection of CAD: Symptomatic-Acute Chest Pain (use of CT angiogram)	I (1)
<ul style="list-style-type: none"> High pre-test probability of CAD ECG-ST-segment elevation and/or positive cardiac enzymes 	I (1)
Detection of CAD: Asymptomatic (without chest pain syndrome)-Asymptomatic (use of CT angiogram)	I (1)
<ul style="list-style-type: none"> Low CHD risk (Framingham risk criteria) Moderate CHD risk (Framingham) 	I (2)
Risk Assessment: General Population-Asymptomatic (Calcium scoring)	I (1)
<ul style="list-style-type: none"> Low CHD risk (Framingham) 	I (1)
Detection of CAD with Prior Test Results-Evaluation of Chest Pain Syndrome (use of CT angiogram)	I (2)
<ul style="list-style-type: none"> Evidence of moderate to severe ischemia on stress test (exercise, perfusion, or stress echo) 	I (2)
Risk Assessment with Prior Test Results-Asymptomatic (Calcium Scoring)	I (1)
<ul style="list-style-type: none"> Prior calcium score within previous 5 years 	I (1)

Henkel RC et al. JACC September 2006

Appropriate Indications for CT

Indication	Appropriateness Criteria (Median Score)
Detection of CAD: Symptomatic - Evaluation of Chest Pain Syndrome (use of CT angiogram)	A (7)
<ul style="list-style-type: none"> Intermediate pre-test probability of CAD ECG uninterpretable OR unable to exercise 	A (7)
Detection of CAD: Symptomatic - Evaluation of Intra-Cardiac Structures (use of CT angiogram)	A (9)
<ul style="list-style-type: none"> Evaluation of suspected coronary anomalies 	A (9)
Detection of CAD: Symptomatic - Acute Chest Pain (use of CT angiogram)	A (7)
<ul style="list-style-type: none"> Intermediate pre-test probability of CAD No ECG changes and serial enzymes negative 	A (7)
Detection of CAD with Prior Test Results - Evaluation of Chest Pain Syndrome (use of CT angiogram)	A (8)
<ul style="list-style-type: none"> Uninterpretable or equivocal stress test (exercise, perfusion or stress echo) 	A (8)
Structure and Function-Morphology (use of CT angiogram)	A (7)
<ul style="list-style-type: none"> Assessment of complex congenital heart disease including anomalies of coronary circulation, great vessels, and cardiac chambers and coronary arteries in patients with new onset heart failure to assess etiology 	A (7)

Henkel RC et al. JACC September 2006


Imaging Assessment of Myocardial Viability

Definitions

- **Stunned Myocardium**
 - Acute MI
 - Decreased function
 - Normal blood flow
 - Has the potential to recover function
- **Hibernating Myocardium**
 - Reduced contraction at rest
 - Chronically reduced blood flow
 - Function can improve after revascularization
- **Nonviable Myocardium**
 - Cell death of myocytes and replacement of myocytes by fibrosis or scar tissue
 - Lack of recovery of normal function after revascularization

Viability Imaging and Functional Improvement





Improvement in Regional LV Function after CABG/PTCA (%)




Kloner et al, Circulation 1998; 97:1848

Methods for Assessing Viable Myocardium


- **Assessment of myocardial metabolism/Cell integrity/perfusion: nuclear techniques**
- **Assessment of extent of necrosis: MRI**
- **Contractile reserve: dobutamine echo**



CMR and viability




DHE-MRI vs. SPECT



DHE-MRI has ~ 10 fold greater spatial resolution than SPECT


MRI versus PET

- Good agreement between DHE-MRI and PET for detecting viability
- However, 11% segments deemed viable by PET showed a scar by MRI



Klein C et al. Circulation 2002 Jan 15;105(2):162-7

Extent of Scar on MRI and Prognosis



Kwon D, Desai MY et al. JACC Imaging

Guidelines for Stress and Viability Testing

- Class I
 - Diagnosis of myocardial ischemia in symptomatic patients.
 - Hibernating myocardium
 - For targeted intervention
 - Assessment for restenosis after revascularization in patients
 - With atypical recurrent symptoms.
- Class IIA
 - After revascularization in patients with typical recurrent symptoms.
 - In patients unable to exercise or in whom ECG is less reliable
 - After cardiac transplantation.
 - In women with intermediate pretest likelihood of CAD
- Class III
 - Asymptomatic persons with low likelihood of CAD
 - Routine periodic reassessment of stable patients for whom no change in therapy is contemplated
 - Routine reassessment of asymptomatic patients after revascularization

© 2008 American Heart Association

Circulation. 2008 Mar 18;117(11):1478-97

Valvular heart disease


- Echo remains the primary diagnostic modality for valvular heart disease
- CMR for accurate LV volumetric assessment
- Emerging role of MDCT in planning prior to percutaneous valve procedures

© 2008 American Heart Association

Different Etiologies of MR




Mitral valve prolapse



Papillary muscle rupture

© 2008 American Heart Association

3D echo




Normal mitral valve from LA



Mitral valve with P2 flail from LA


© 2008 American Heart Association

CT and CMR and mitral valve morphology




© 2010 Philips Medical Systems

Aortic valve disease




© 2010 Philips Medical Systems

Aortic valve




© 2010 Philips Medical Systems

SBE and ring abscess: AI with poor leaflet coaptation



© 2010 Philips Medical Systems

Prosthetic Valves




Role of Imaging in Electrophysiology

CRT Applications
A Fib applications




Echo techniques and CRT

- **Septal to Posterior Wall Mechanical Delay (SPWMD)**
 - M-mode
- **Tissue Doppler Imaging (TDI)**
 - PW TDI
 - Time to onset or peak systolic myocardial velocities
 - Color TDI
 - Time to peak systolic myocardial velocities



CT and Cardiac Veins






- ### Imaging and Cardiomyopathies
- Echo is first line modality
 - CMR is widely gaining prominence
 - Tissue characterization is key
 - Emerging role of MDCT

Hypertrophic CMP: Echocardiography




Cardiac Magnetic Resonance



In 6 % patients, CMR accurately diagnosed HCM missed on echocardiography


Rickers et al. Circulation 2005;112:855-61
Spirito P et al. N Engl J Med 342: 1778-1785

Abnormal Papillary Muscles and Dynamic LVOT Obstruction




Kwon D, Desai MY et al. Heart August 2007

CMR, Fibrosis and HCM: No specific pattern



Amyloidosis



© 2004 American Heart Association


•Cox Proportional Hazard Analysis

Variable	χ^2	p-value
DHE-CMR Positive	4.91	0.03
Age	3.8	0.05
NYHA Class	3.3	0.07
Low voltage on ECG	0.67	0.41
Interventricular septal thickness	1.7	0.19
E/E' > 15 on Doppler echocardiography	1.12	0.29
Doppler echocardiography \leq 150	1.41	0.23
Myocardial performance index	2.10	0.15
Diastology grade	0.35	0.55

© 2004 American Heart Association

Austin B. Desai MY: JACC 2009


Myocarditis



© 2004 American Heart Association

Marholdt et al. 2004. Circulation 109:1250-8


ARVD



© 2004 American Heart Association

Bluemke et al. Cardiology. 2003. 99:153-62

Sarcoidosis




- Normal or impaired LVEF
- Edema around granulomas
- Patchy DHE
 - Usually basal-mid anteroseptal and basal lateral segments
- Sens 100%, spec 78% in 58 patients

Smedema JP. JACC 2005;45:1683-90.

Assessment of the Pericardium

Echocardiography remains the initial modality of choice



Constrictive pericarditis



Associated with pericardial thickening, calcification, tethering, diastolic septal bounce, conical deformity of the ventricles


Congenital Heart Disease

Echo is a first start, but tomographic imaging is vital




Cardiac masses

- **Echo is mainstay of initial diagnosis**
 - In classic benign lesions, might not need anything else (eg. myxoma, papillary fibroelastomas etc)
- **However, multimodality imaging (CMR +/- CT) generally very useful**
 - Evaluate for satellite lesions
 - Tissue characterization
 - Extracardiac involvement



MSCT in Cardiac Masses



Intramuscular Lipoma

Spindle cell carcinoma

Appropriate Indications for CT and CMR in Structural heart disease


Structure and Function-Evaluation of intra- and extra-cardiac structures

- Evaluation of cardiac mass (suspected tumor or thrombus) A (8)
- Patients with technically limited images from Echo or TEE A (8)
- Evaluation of pericardial conditions (pericardial mass, constrictive pericarditis, or complications of cardiac surgery) A (8)
- Evaluation of pulmonary vein anatomy prior to invasive radiofrequency ablation for atrial fibrillation A (8)
- Noninvasive coronary vein mapping prior to placement of biventricular pacemaker A (8)
- Noninvasive coronary arterial mapping, including internal mammary artery prior to repeat cardiac surgical revascularization A (8)


Structure and Function - Evaluation of Aortic and Pulmonary Disease)

- Evaluation of suspected aortic dissection or thoracic aortic aneurysm A (9)
- Evaluation of suspected pulmonary embolism A (9)

How Does all This Work Politically??



Manhattan Project



Conclusions

- **Multi-modality cardiac imaging has a potential diagnostic role in every facet of cardiovascular medicine**
 - Extremely vital in ischemic heart disease; reduce number of invasive procedures
 - Emerging important role in EPS
 - Non-coronary cardiovascular evaluation
- **JUST HAVE TO KNOW WHEN TO USE, HOW TO USE AND MORE IMPORTANTLY WHEN NOT TO USE**
- **Collaboration between cardiology and radiology is key**

© 2010 American College of Radiology